Chiara Lazzari

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Imane Chaib, Niki Karachaliou, Sara Pilotto et al. · JNCI Journal of the National Cancer Institute · 2017 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel Shao-Weng Tan, Tomasso De Pas et al. · Clinical Cancer Research · 2015 · 178 citations · Full text

Medicine, Oncology, Pharmacology +17

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors

Enrico Milan, Chiara Lazzari, Santosh Anand et al. · Journal of Proteomics · 2012 · 78 citations

Medicine, Cancer Biology, Oncology +11

Differential Role of Transcription-Coupled Repair in UVB–Induced Response of Human Fibroblasts and Keratinocytes

Mariarosaria D’Errico, Massimo Teson, A. Calcagnile et al. · Cancer Research · 2005 · 64 citations · Full text

Life Sciences, Dermatology, Molecular Biology +17